Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 21,412 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase II Clear all

Conditions: Glioblastoma
Interventions: Gross total resection and Gliadel(R) wafers implanted, GammaKnife(R) stereotactic Radiosurgery, Standard fractionated radiation therapy, Temozolomide; Procedure · Radiation · Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Hepatoma, Liver Neoplasms, Adenoma, Liver Cell, Carcinoma, Hepatocellular, Liver Neoplasms, Experimental
Interventions: TRC 105, Sorafenib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non Small Cell Lung Cancer, Lung Cancer
Interventions: ABT-751 and Carboplatin; Drug
Lead sponsor: Konstantin Dragnev; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Hepatitis B
Interventions: IFN-γ 1b (Actimmune), Adefovir dipivoxil, IFN-γ 1b and Adefovir dipivoxil combination; Drug
Lead sponsor: Huntington Medical Research Institutes; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Overweight and Obesity, Physical Inactivity
Interventions: Move physical activity support program; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pancreatic Cancer
Interventions: Gemcitabine, Dendritic Cell Immunotherapy; Drug · Procedure
Lead sponsor: George Albert Fisher; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 1 Diabetes
Interventions: Simvastatin; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 20 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory
Interventions: Mogamulizumab; Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Duarte, California • Irvine, California • Stanford, California + 4 more

Conditions: Kidney Cancer
Interventions: INC280; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia
Interventions: Azacitidine; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 60 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 2
States / cities: Tampa, Florida • Durham, North Carolina

Conditions: Substance-Related Disorders, Alcohol-Related Disorders
Interventions: The Women's Recovery Group, Group Drug Counseling; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Belmont, Massachusetts • Fall River, Massachusetts

Conditions: Anesthesia
Interventions: Dexmedetomidine, Midazolam, Fentanyl, Morphine; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 28 Weeks to 36 Weeks
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 4
States / cities: Louisville, Kentucky • Pittsburgh, Pennsylvania • Greenville, South Carolina + 1 more

Conditions: Colorectal Cancer
Interventions: brivudine phosphoramidate; Drug
Lead sponsor: NewBiotics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Thyroid Cancer
Interventions: IMRT, DWI MRI, Doxorubicin, Modified Barium Swallow Impairment Profile (MBSImP); Radiation · Device · Drug + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage III Non-small Cell Lung Cancer, Stage I Pancreatic Cancer, Stage II Non-small Cell Lung Cancer, Stage IVB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage IVA Pancreatic Cancer
Interventions: Detox-B adjuvant, ras peptide cancer vaccine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Timeline: Started 1995
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HER2 Positive Metastatic Breast Cancer
Interventions: ARX788; Drug
Lead sponsor: Ambrx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 22 more

Conditions: Breast Cancer
Interventions: ixabepilone; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 2
States / cities: New York, New York

Conditions: Breast Cancer, Chest Wall Disease
Interventions: Pembrolizumab, Carboplatin, Trastuzumab; Biological · Drug
Lead sponsor: Laura Huppert, MD, BA; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more

Conditions: Glioblastoma, Recurrent Glioblastoma
Interventions: Pembrolizumab, Olaparib, Temozolomide; Drug
Lead sponsor: L. Nicolas Gonzalez Castro, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York

Conditions: Pigmented Villonodular Synovitis, TGCT, Tenosynovial Giant Cell Tumor
Interventions: AMB-05X; Biological
Lead sponsor: AmMax Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Sacramento, California • Miami, Florida • Houston, Texas

Conditions: Mucosal Melanoma, Acral/Lentiginous Melanoma, Chronically Sun Damaged Melanomas
Interventions: Imatinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 5
States / cities: Denver, Colorado • Tampa, Florida • Chicago, Illinois + 2 more

Conditions: Prostate Carcinoma, Benign Prostatic Hyperplasia
Interventions: Merit Medical Embospheres, Radiation Therapy; Device · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 50 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Common Wart, Warts Hand, Warts, Papillomavirus Infections, DNA Virus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Virus Diseases, Tumor Virus Infections, Verruca Vulgaris, Verruca
Interventions: VP-102 Cantharidin, topical film forming solution; Combination Product
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Little Rock, Arkansas • Jacksonville, Florida • Plainfield, Indiana + 2 more

Conditions: Brain Neoplasms, Adult, Malignant
Interventions: Radiotherapy; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM

Sorafenib and TRC105 in Hepatocellular Cancer

Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer

A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B

A 12-week Field Trial of the Move Physical Activity Support Program

Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer

Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy

Women's Recovery Group (WRG) Study - A Randomized Controlled Stage II Trial

Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age

NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

BMS-247550 in Treating Women With Metastatic Breast Cancer

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Surgical Pembro +/- Olaparib w TMZ for rGBM

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Cantharidin and Occlusion in Verruca Epithelium

Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases